OBJECTIVES: To evaluate the prevalence and risk factors of anal squamous intraepithelial lesions (ASIL), the putative anal cancer precursor, in Asian HIV positive and HIV negative men who have sex with men (MSM). METHODS: Men who underwent anal Pap smear reported clinical, sociodemographic and behavioural information collected through questionnaire and interview between January 2007 and April 2008. Chi(2) and logistic regression were used to evaluate ASIL prevalence and risk factors among HIV positive and HIV negative MSM. RESULTS: Of the 174 MSM (mean age 32.1 years), 118 (67.8%) were HIV positive. Overall, 27% had abnormal anal cytology: 13.2% had atypical squamous cells of undetermined significance (ASC-US), 11.5% had low-grade squamous intraepithelial lesion (LSIL) and 2.3% had high-grade squamous intraepithelial lesion (HSIL). Prevalence of ASIL was higher among HIV positive than HIV negative MSM (33.9% vs 12.5%; p = 0.003). Among HIV positive MSM, 16.1% had ASC-US, 14.4% had LSIL and 3.4% had HSIL and 7.1%, 5.4% and 0% in HIV negative MSM, respectively. Anal condyloma was detected in 22% of HIV positive and 16.1% (9/56) of HIV negative MSM (p = 0.5). In HIV positive MSM, anal condyloma (OR 3.42, 95% CI 1.29 to 9.04; p = 0.01) was a significant risk factor for ASIL. Highly active antiretroviral therapy use and CD4+ T cell count were not associated with ASIL. CONCLUSIONS: One-third of HIV positive and 12.5% of HIV negative MSM had ASIL. Thus, as greater numbers of HIV positive MSM live longer due to increasing access to HAART worldwide, effective strategies to screen and manage anal precancerous lesions are needed.
OBJECTIVES: To evaluate the prevalence and risk factors of anal squamous intraepithelial lesions (ASIL), the putative anal cancer precursor, in Asian HIV positive and HIV negative men who have sex with men (MSM). METHODS:Men who underwent anal Pap smear reported clinical, sociodemographic and behavioural information collected through questionnaire and interview between January 2007 and April 2008. Chi(2) and logistic regression were used to evaluate ASIL prevalence and risk factors among HIV positive and HIV negative MSM. RESULTS: Of the 174 MSM (mean age 32.1 years), 118 (67.8%) were HIV positive. Overall, 27% had abnormal anal cytology: 13.2% had atypical squamous cells of undetermined significance (ASC-US), 11.5% had low-grade squamous intraepithelial lesion (LSIL) and 2.3% had high-grade squamous intraepithelial lesion (HSIL). Prevalence of ASIL was higher among HIV positive than HIV negative MSM (33.9% vs 12.5%; p = 0.003). Among HIV positive MSM, 16.1% had ASC-US, 14.4% had LSIL and 3.4% had HSIL and 7.1%, 5.4% and 0% in HIV negative MSM, respectively. Anal condyloma was detected in 22% of HIV positive and 16.1% (9/56) of HIV negative MSM (p = 0.5). In HIV positive MSM, anal condyloma (OR 3.42, 95% CI 1.29 to 9.04; p = 0.01) was a significant risk factor for ASIL. Highly active antiretroviral therapy use and CD4+ T cell count were not associated with ASIL. CONCLUSIONS: One-third of HIV positive and 12.5% of HIV negative MSM had ASIL. Thus, as greater numbers of HIV positive MSM live longer due to increasing access to HAART worldwide, effective strategies to screen and manage anal precancerous lesions are needed.
Authors: Frits van Griensven; Peter H Kilmarx; Supaporn Jeeyapant; Chomnad Manopaiboon; Supaporn Korattana; Richard A Jenkins; Wat Uthaivoravit; Khanchit Limpakarnjanarat; Timothy D Mastro Journal: Arch Sex Behav Date: 2004-04
Authors: Diane Solomon; Diane Davey; Robert Kurman; Ann Moriarty; Dennis O'Connor; Marianne Prey; Stephen Raab; Mark Sherman; David Wilbur; Thomas Wright; Nancy Young Journal: JAMA Date: 2002-04-24 Impact factor: 56.272
Authors: Somsamorn Mangclaviraj; Stephen J Kerr; Surasith Chaithongwongwatthana; Jintanat Ananworanich; Bernard Hirschel; Sean Emery; David A Cooper; Pichai Chotnopparatpattara; Kiat Ruxrungtham; Praphan Phanuphak Journal: Int J STD AIDS Date: 2008-08 Impact factor: 1.359
Authors: Lisa G Johnson; Margaret M Madeleine; Laura M Newcomer; Stephen M Schwartz; Janet R Daling Journal: Cancer Date: 2004-07-15 Impact factor: 6.860
Authors: Christophe Piketty; Teresa M Darragh; Isabelle Heard; Maria Da Costa; Patrick Bruneval; Michel D Kazatchkine; Joel M Palefsky Journal: Sex Transm Dis Date: 2004-02 Impact factor: 2.830
Authors: Lori A Panther; Katiri Wagner; JoAnn Proper; Dana K Fugelso; Pamela A Chatis; Will Weeden; Imad A Nasser; John P Doweiko; Bruce J Dezube Journal: Clin Infect Dis Date: 2004-04-21 Impact factor: 9.079
Authors: G A Binda; G Gagliardi; I Dal Conte; M Verra; P Cassoni; E Cavazzoni; E Stocco; S Delmonte; P De Nardi; L Sticchi; M Mistrangelo Journal: Tech Coloproctol Date: 2019-06-26 Impact factor: 3.781
Authors: Meredith S Shiels; Ruth M Pfeiffer; Anil K Chaturvedi; Aimee R Kreimer; Eric A Engels Journal: J Natl Cancer Inst Date: 2012-10-05 Impact factor: 13.506
Authors: Brandon Brown; Mariam Davtyan; Segundo R Leon; Hugo Sanchez; Gino Calvo; Jeffrey D Klausner; Jerome Galea Journal: BMJ Open Date: 2014-09-16 Impact factor: 2.692